TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE B-

NCT07367516: A Phase Ib/II Clinical Trial Evaluating the Safety and Efficacy of TQB6411 Injection in Participant s With Recurrent or Metastatic Esophageal Cancer Who Have Failed Prior PD-1/PD-L1 Inhibitor Plus Platinum-Based Chemothe

Sponsor: Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · Phase: PHASE1/PHASE2 · Area: ONCOLOGY · Target Enrollment: 105 pts

Competing Trials Overlap

2 Active Trials

Excess Burn Exposure

$746,130

Rescue Site Savings

+$510,510

Unlock Full NCT07367516 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07367516 Rescue Dossier →